Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- Trial result
Small cell lung cancer
Tarlatamab CD3×DLL3 T-cell engager lifts median OS to 13.6 mo after platinum-relapsed SCLC
Tarlatamab is a bispecific that redirects T cells to DLL3-positive neuroendocrine cells. In the phase 3, open-label DeLLphi-304 trial (NCT05740566) 509 small-cell lung cancer patients who had progressed on platinum…
NCT05740566 - Trial result
Small cell lung cancer
Obrixtamig (BI 764532) + Topotecan Doubles Typical Second-Line Response in Platinum-Relapsed SCLC
Obrixtamig is an IgG-like bispecific T-cell engager that binds DLL3 on tumor cells and CD3 on T cells, while topotecan is the long-standing topoisomerase-I standard for relapsed small-cell lung cancer (SCLC). In the…
NCT05990738 - Trial result
Breast cancer
ESG401 TROP2-Directed ADC Hits 83% ORR First-Line TNBC, ~35% in Heavily Pretreated Breast Cancers
ESG401, an ADC consisting of humanized anti-TROP2 IgG1 conjugated to SN-38. ESG401 was evaluated in the phase 1 ESG401-101 study in China (NCT04892342) across 156 patients with metastatic breast and other solid…
NCT04892342 - Trial result
Breast cancer
Inavolisib Adds 7 Months OS atop Palbo-Fulvestrant in PIK3CA-Mutant HR⁺/HER2- MBC
In the Phase 3 double-blind INAVO120 trial (NCT04191499), 161 women with endocrine-resistant, PIK3CA-mutated HR+⁺/HER2- metastatic breast cancer received the PI3Kα inhibitor inavolisib plus palbociclib-fulvestrant;…
NCT04191499 - Trial result
Breast cancer
12-Week Dual-HER2 ± Paclitaxel Delivers 97% 5-Yr OS in De-Escalated HER2-Positive Early Breast Cancer
A pooled analysis of 713 patients from three trials (NCT01817452, NCT01779206, NCT03272477) tested short-course neoadjuvant regimens—trastuzumab + pertuzumab with or without 12 weekly paclitaxel, or antibody–drug…
NCT01817452 - Trial result
Breast cancer
Alpelisib + Sacituzumab Govitecan Yields 36% ORR (50% in TNBC) at Recommended Phase-2 Dose
In a 3 + 3 phase I dose-escalation study (NCT05143229), 12 women with heavily pre-treated, HER2-negative metastatic breast cancer received daily alpelisib (an α-specific PI3K inhibitor) plus sacituzumab govitecan (A…
NCT05143229 - Trial result
Breast cancer
ctDNA Surveillance Pinpoints Relapse Risk in High-Risk ER+/HER2- Breast Cancer—Early Clearance Triples on Palbo + Fulvestrant
In the multicenter DARE trial (NCT04567420), 552 high-risk ER+/HER2- patients on adjuvant endocrine therapy underwent Signatera™ ctDNA testing every 6 mo. Over a median 27 mo, 432 remained ctDNA-negative and showed a…
NCT04567420 - Trial result
Brain and CNS tumors
B7-H3 CAR-T Infusions Via Dual Ommaya Reservoirs Show 14.6-mo Median OS in Recurrent Glioblastoma
B7-H3 is over-expressed in >70% of glioblastomas, and an intracranial B7-H3–directed autologous CAR-T product was tested in a first-in-human, dose-escalation Phase 1 study (NCT05474378). Nine heavily pre-treated…
NCT05474378 - Trial result
Brain and CNS tumors
Adjuvant TTFields + Pembrolizumab + Temozolomide Lifts mPFS to 12 mo in Newly Diagnosed GBM
TTFields therapy activates type-I-interferon signalling. This single-arm phase 2 study (NCT03405792) evaluated whether adding a PD-1 blockade to the EF-14 backbone could matter. Twenty-six patients,…
NCT03405792 - Trial result
Brain and CNS tumors
CARv3-TEAM-E Dual-EGFR CAR-T Shows 0 DLTs and 6-Month Stable Disease in Recurrent GBM
CARv3-TEAM-E is a second-generation CAR-T construct that targets the mutant neoantigen EGFRvIII and secretes a T-cell–engaging antibody against wild-type EGFR, aiming to overcome glioblastoma’s antigen heterogeneity.…
NCT05660369 - Trial result
Colorectal cancer
First-line encorafenib + cetuximab + mFOLFOX6 doubles survival to 30 mo in BRAF-V600E metastatic CRC
Encorafenib (BRAF V600E inhibitor) plus cetuximab (EGFR mAb) and mFOLFOX6 chemotherapy was tested against investigator-choice oxaliplatin-based chemotherapy ± bevacizumab in the phase 3 BREAKWATER trial…
NCT04607421 - Trial result
Colorectal cancer
DSP107 (CD47×4-1BB) + atezolizumab doubles survival and controls disease in 62% of refractory MSS colorectal cancers
DSP107 is a bi-specific fusion protein that tethers trimeric 4-1BBL to CD47 overexpressed on tumour cells, delivering conditional activation of immune response.. In a phase 2 expansion (NCT04440735), 50 heavily…
NCT04440735 - Trial result
Stomach and esophageal cancer
Zanidatamab + chemo posts 76% ORR and 36.5-mo OS as 1L HER2-positive gastro-oesophageal therapy
Zanidatamab, a bispecific HER2-targeted antibody that dimer-locks domains 2 & 4, was combined with CAPOX, FP or mFOLFOX6 in a single-arm, multicentre phase 2 study (NCT03929666). Among 46 treatment-naïve, metastatic…
NCT03929666 - Trial result
Stomach and esophageal cancer
Trastuzumab deruxtecan tops ramucirumab + paclitaxel for 2L HER2-positive gastric cancer, lifting mOS to 14.7 mo
Trastuzumab deruxtecan (T-DXd), a HER2-directed antibody–drug conjugate, was pitted against standard ramucirumab + paclitaxel in the global phase 3 DESTINY-Gastric04 trial (NCT04704934). 494 patients with…
NCT04704934 - Trial result
Pancreatic cancer
Oral Salmonella-IL2 bacteria + systemic FOLFIRINOX triples median PFS to 15 mo in stage IV pancreatic cancer
Salmonella-IL2, an attenuated *S. Typhimurium* engineered to secrete human IL-2 and colonize tumors, was administered orally alongside bi-weekly FOLFIRINOX in a non-randomized Phase II study (NCT04589234). 20…
NCT04589234 - Trial result
Pancreatic cancer
Motixafortide (CXCR4i) + cemiplimab/PD-1 with gem/nab-paclitaxel logs 63% PR and 9.6-mo PFS in 1L metastatic PDAC
In the Phase 1 “signal-seeking” CheMo4METPANC study (NCT04543071), eleven treatment-naïve patients with metastatic pancreatic cancer received motixafortide (CXCR4i), cemiplimab, gemcitabine (1000 mg/m²) +…
NCT04543071 - Trial result
Pancreatic cancer
Surufatinib (VEGFR/FGFR/CSF-1R TKI) + KN046 (PD-L1/CTLA-4 bispecific) with gem/nab-paclitaxel delivers 69% ORR in first-line advanced pancreatic cancer
Surufatinib, an oral multi-kinase inhibitor of VEGFR1-3, FGFR1 and CSF-1R, was combined with KN046, a dual PD-L1/CTLA-4 antibody, and the chemotherapy backbone gemcitabine 1000 mg/m² + nab-paclitaxel 125 mg/m² (q3w)…
NCT05832892 - Trial result
Pancreatic cancer
Avutometinib (RAF/MEK clamp) + defactinib (FAK i) with gem/nab-paclitaxel pushes ORR to 83% in first-line metastatic PDAC
Avutometinib and defactinib were combined with standard gemcitabine (800–1000 mg/m)² + nab-paclitaxel (100–125 mg/m²) in the Phase Ib/II RAMP-205 trial (NCT05669482). Among 54 newly diagnosed metastatic PDAC patients…
NCT05669482 - Trial result
Pancreatic cancer
Adaptive FOLFIRINOX→gem/nab-paclitaxel (plus losartan) drives 88–100% R0 resections in localized pancreatic cancer
The NeoOPTIMIZE study evaluated a “fail-fast” neoadjuvant strategy: 43 resectable/borderline/locally advanced PDAC patients began with four cycles of FOLFIRINOX + daily losartan (angiotensin II receptor blocker…
- Trial result
Sarcoma and GIST
NB003 Broad-Spectrum KIT Inhibitor Delivers ≈43% ORR and 13.8-mo mPFS in 4th-Line GIST
NB003 is an oral tyrosine-kinase inhibitor engineered to hit both ATP-binding–site (ex13/14) and activation-loop (ex17/18) KIT resistance mutations that undercut imatinib and next-gen agents. In the phase 1…
NCT04936178 - Trial result
Stomach and esophageal cancer
NOTCH1-Mutant Esophageal Squamous Cell Carcinoma (ESCC) AchievesGets 18.4 month OS on Tislelizumab—HR 0.35 vs Chemo
Tislelizumab, an anti-PD-1 antibody, was pitted against investigator-choice paclitaxel/docetaxel/irinotecan in the Phase III RATIONALE-302 trial (second-line advanced/metastatic ESCC; NCT03430843). Comprehensive…
NCT03430843 - Trial result
Liver and bile duct cancer
Rilvegostomig (PD-1/TIGIT bispecific) + gemcitabine/cisplatin lifts mPFS to 8.3 months in front-line biliary tract cancer
Rilvegostomig, an IgG1 bispecific antibody simultaneously blocking PD-1 and TIGIT, was combined with standard gemcitabine 1000 mg/m² + cisplatin 25 mg/m² (Days 1, 8 Q3W) in the Phase 2 GEMINI-Hepatobiliary substudy 2…
NCT05775159 - Trial result
Kidney cancer
Cabozantinib Alone Matches Cabo + Atezolizumab After 1L IO Combos in RCC with 10-month mPFS
Cabozantinib, an oral VEGFR/MET/AXL TKI, monotherapy was compared with cabozantinib + atezolizumab (anti-PD-L1 antibody) in a CONTACT-03 (NCT04338269) subgroup of 236 advanced renal-cell carcinoma patients whose…
NCT04338269 - Trial result
Kidney cancer
Casdatifan (HIF-2α) + cabozantinib logs 41% ORR in previously treated clear-cell RCC
Casdatifan, an oral hypoxia-inducible-factor-2α inhibitor, combined with cabozantinib (VEGFR-TKI) in the Phase 1 ARC-20 expansion (NCT05536141). Twenty-seven adults with IO-exposed ± VEGFR-TKI clear-cell RCC received…
NCT05536141 - Trial result
Bladder and urothelial cancer
Detalimogene voraplasmid (EG-70) non-viral IL-12/RIG-I gene therapy achieves 73% complete response in BCG-unresponsive NMIBC, Phase 2 LEGEND trial now enrolling broader cohorts
Detalimogene voraplasmid is an intravesical, non-integrating plasmid that co-expresses IL-12 and a RIG-I agonist to trigger local innate and adaptive immunity. In the Phase 1 dose-escalation of the open-label LEGEND…
NCT04752722 - Trial result
Bladder and urothelial cancer
Zelenectide Pevedotin (Nectin-4 BTC) + Pembrolizumab Delivers 65% ORR (25% CR) in First-Line Cisplatin-Ineligible Urothelial Cancer
Zelenectide pevedotin is a “Bicycle” toxin conjugate that targets Nectin-4 and releases MMAE. When combined with a PD-1 blockade, it aims to rapidly induce cytotoxicity while also priming the immune system. In…
NCT04561362 - Trial result
Prostate cancer
Gotistobart (pH-sensitive anti-CTLA-4) + 177Lu-PSMA-617 logs 67% PSA50 with no DLTs in dose-escalation mCRPC
Gotistobart, a recycling-preserving CTLA-4 antibody that selectively depletes intratumoral Tregs, was paired with standard Lu 177 vipivotide tetraxetan radioligand therapy in the PRESERVE-006 Phase 1 dose-escalation…
NCT05682443 - Trial result
Ovarian cancer
LY4170156 Exatecan-Linker FRα ADC Delivers 55% ORR in Late-Line Platinum-Resistant Ovarian Cancer
LY4170156 is an Fc-silent antibody–drug conjugate targeting folate-receptor-α, armed with an exatecan payload via a polysarcosine linker. In platinum resistant ovarian cancer, 35-40% of tumors have high FRα…
NCT06400472 - Trial result
Ovarian cancer
CUSP06 CDH6-Targeted Exatecan ADC Shows 36% ORR (50% at ≥4 mg/kg) in Biomarker-Unselected Platinum Refractory/-Resistant Ovarian Cancer
CUSP06 is a cadherin-6 (CDH6)–directed antibody-drug conjugate bearing an exatecan payload (DAR 8) given Q3W in the first-in-human Phase 1a study CUSP06-1001 (NCT06234423). An estimated 65-85% of patients with…
NCT06234423 - Trial result
Ovarian cancer
Pembrolizumab + Lenvatinib (PD-1 + VEGFR/MET/FGFR TKI) Hits 30% ORR and 76% 6-mo PFS in Chemoresistant Clear-Cell Ovarian Cancer
Pembrolizumab, an anti-PD-1 antibody, was paired with the multi-kinase anti-angiogenic agent lenvatinib in a two-stage, single-arm phase 2 trial (NCT05296512). Thirty women with recurrent or persistent clear-cell…
NCT05296512
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.